MORGAN STANLEY PLC/CALL/BIOGEN IDEC/200/0.01/20.06.25 | Real-time Bid/Ask 09:07:58 12/07/2024 BST | ||
| 0.55 EUR / 0.57 EUR | +3.70% |
|
| Current month | +3.85% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 12/07/24 | 0.55 | +1.85% |
| 11/07/24 | 0.54 | +3.85% |
| 10/07/24 | 0.52 | +8.33% |
| 09/07/24 | 0.48 | 0.00% |
| 08/07/24 | 0.48 | 0.00% |
Delayed Quote Börse Stuttgart
Last update July 12, 2024 at 08:37 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | Morgan Stanley |
| WKN | MG6CCZ |
| ISIN | DE000MG6CCZ3 |
| Date issued | 20/06/2024 |
| Strike | 200 $ |
| Maturity | 20/06/2025 (344 Days) |
| Parity | 100 : 1 |
| Emission price | 0.54 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.57 € |
|---|---|
| Lowest since issue | 0.46 € |
| Spread | 0.02 € |
| Spread % | 3.51% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
35
Last Close Price
236.8
USD
Average target price
282
USD
Spread / Average Target
+19.10%
- Stock Market
- Warrants
- Warrant
